deferoxamine has been researched along with Deafness, Transitory in 7 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirteen patients (35." | 1.39 | Audiologic and vestibular assessment in patients with β-thalassemia major receiving long-term transfusion therapy. ( Chao, YH; Lin, CD; Lin, CY; Peng, CT; Tsai, MH; Wu, HP; Wu, KH, 2013) |
| "To determine the frequency of eye and auditory complications and their relationship to drug dosage and iron stores in patients receiving deferoxamine, we studied 52 regularly transfused patients who received deferoxamine by subcutaneous or intravenous infusion in doses from 26 to 136 mg/kg/day, and whose serum ferritin levels of 185 to 17,775 micrograms/L reflected a wide range of iron stores." | 1.28 | Vision and hearing during deferoxamine therapy. ( Cohen, A; Konkle, DF; Martin, M; Mizanin, J; Schwartz, E, 1990) |
| "When deferoxamine therapy was discontinued and serial studies were performed, audiograms in seven cases reverted to normal or near normal within two to three weeks, and nine of 13 patients with symptoms became asymptomatic." | 1.27 | Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy. ( Boyden, MH; Carley, H; Freedman, MH; Gallant, LA; Gallant, T, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chao, YH | 1 |
| Wu, KH | 1 |
| Lin, CY | 1 |
| Tsai, MH | 1 |
| Peng, CT | 1 |
| Wu, HP | 1 |
| Lin, CD | 1 |
| Thio, D | 1 |
| Prasad, V | 1 |
| Anslow, P | 1 |
| Lennox, P | 1 |
| Giardina, PJ | 1 |
| Grady, RW | 1 |
| Cohen, A | 1 |
| Martin, M | 1 |
| Mizanin, J | 1 |
| Konkle, DF | 1 |
| Schwartz, E | 1 |
| Wonke, B | 1 |
| Hoffbrand, AV | 1 |
| Aldouri, M | 1 |
| Wickens, D | 1 |
| Flynn, D | 1 |
| Stearns, M | 1 |
| Warner, P | 1 |
| Cases, A | 1 |
| Kelly, J | 1 |
| Sabater, J | 1 |
| Campistol, JM | 1 |
| Torras, A | 1 |
| Montoliu, J | 1 |
| López, I | 1 |
| Revert, L | 1 |
| Gallant, T | 1 |
| Boyden, MH | 1 |
| Gallant, LA | 1 |
| Carley, H | 1 |
| Freedman, MH | 1 |
1 review available for deferoxamine and Deafness, Transitory
| Article | Year |
|---|---|
Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
Topics: Adolescent; Adult; Chelating Agents; Chelation Therapy; Child; Deferoxamine; Growth Disorders; Heari | 1995 |
6 other studies available for deferoxamine and Deafness, Transitory
| Article | Year |
|---|---|
Audiologic and vestibular assessment in patients with β-thalassemia major receiving long-term transfusion therapy.
Topics: Acoustic Impedance Tests; Adolescent; Adult; Audiometry, Pure-Tone; beta-Thalassemia; Blood Transfus | 2013 |
Marrow proliferation as a cause of hearing loss in beta-thalassaemia major.
Topics: beta-Thalassemia; Bone Marrow Diseases; Child; Deferoxamine; Hearing Loss; Humans; Male; Siderophore | 2008 |
Vision and hearing during deferoxamine therapy.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Chelation Therapy; Child; Deferoxamine; Ferritins; Hearing L | 1990 |
Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA.
Topics: Adolescent; Adult; Audiometry; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Female; Fer | 1989 |
Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine.
Topics: Acute Disease; Adult; Aged; Deferoxamine; Female; Hearing Loss; Hearing Loss, Bilateral; Hearing Los | 1988 |
Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.
Topics: Adolescent; Adult; Audiometry; Child; Child, Preschool; Deferoxamine; Hearing Loss; Hearing Loss, Hi | 1987 |